PUBT
I'm LongbridgeAI, I can summarize articles.
- Compass Pathways reported 26-week Phase 3 COMP006 data for COMP360 psilocybin in treatment-resistant depression, supporting rapid onset and durable benefit. * In the 25 mg arm, 39% achieved a clinically meaningful MADRS reduction at week 6, with benefit maintained on average through week 26. * Rolling FDA NDA submission is underway, with final submission targeted for Q4 2026. * Launch is planned for the first half of 2027, contingent on FDA approval and subsequent DEA rescheduling. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260707713443) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)